Objective: The effects of mepartricin (S–160) on spontaneous canine benign prostatic hyperplasia (BPH) were investigated by histological, histochemical and biochemical analysis.Methods: Aged beagle dogs (5–9 years old) with spontaneously developed BPH were treated orally with a placebo or S–160 (5, 10 or 20 mg/kg/day) for 8 weeks. The methodology included measurement of prostatic volume by transrectal ultrasonography, qualitative evaluation of prostatic morphology, determination of plasma and intraprostatic estradiol level by radioimmunoassay and immunohistochemical detection of estrogen receptors and androgen receptors in the prostate.Results: S–160 significantly reduced the prostatic volume and regressed histologically the hyperplastic grade of prostate, and also fairly decreased the plasma and intraprostatic estradiol concentration and the estrogen and androgen receptors in the prostate.Conclusions: These results suggest that the reduction of estradiol and estrogen receptors in the prostate may play a crucial role in the regression of BPH by S–160.

Keywords:
Hyperplasia, Sex hormones and receptors, Polyene antibiotic
1.
De Bernardi M, Rollero M, Goi A: Rilievi morfologici della ghiandola prostatica dopo trattamento con mepartricina studio istopatologico sul cane. Acta Toxicol Ther 1986;7:13– 19.
2.
Lotti T, Mirone V, Presioso D, De Bernardi M, Rapocci MP, Ruozi P: Observation on some hormone fraction in patients with benign prostatic hyperplasia treated with mepartricin. Curr Ther Res 1988;44:402–409.
3.
Griffiths K, Coffey D, Cockett A, Di Sant’ Anese A, Ichikawa T, Krieg M, Lee C, McKeehan W, Schalken J, Sciarra F, Steiner G, Sugimura Y, Yamanaka H: The regulation of prostatic growth; in Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (eds): Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Scientific Communication International, 1995, pp 73–115.
4.
Pirke KM, Doerr P: Age–related changes in free plasma testosterone, dihydrotestosterone and estradiol. Acta Endocrinol 1975;80:171– 178.
5.
Rubens RM, Dhont M, Vermeulen A: Futher studies on Leydig cell function in old age. J Clin Endocrinol Metab 1974;39:40–45.
6.
Rannikko S, Adlercreutz H: Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 1983;4:223–229.
7.
Krieg M, Klotzl G, Kaufmann J, Voigt KD: Stroma of human benign prostatic hyperplasia: Preferential tissue for androgen metabolism and oestrogen binding. Acta Endocrinol 1981; 96:422.
8.
Ekman P, Barrack ER, Greene GL, Jensen EV, Walsh PC: Estrogen receptors in human prostate: Evidence for multiple binding site. J Clin Endocrinol Metab 1983;57:166–176.
9.
Walsh PC, Wilson JD: The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 1979;57:1093–1097.
10.
Moore RJ, Gazak JM, Wilson JD: Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17β–estradiol. J Clin Invest 1979;63:351–357.
11.
Trachtenberg J, Hicks LL, Walsh PC: Androgen– and estrogen–receptor content in spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest 1980;65:1051– 1059.
12.
Coffey DS, Walsh PC: Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990;17:461–475.
13.
Takezawa Y, Fukabori Y, Yamanaka H, Mieda M, Honma S, Kushitani M, Hamataki N: Effects of the new steroidal antiandrogen TZP4238 on hormone–induced canine prostatic hyperplasia. Prostate 1992;21:315–329.
14.
Harada M, Kinoshita Y, Moriyama M, Kondo I, Nakahashi M, Kumagai H, Sasaki K, Hosaka M: Histological evaluation of benign prostatic hyperplasia treated by long–term administration of chlormadinone acetate. Prostate 1994; 25:147–155.
15.
Schulze H, Claus S: Histological localization of estrogen receptors in normal and diseased human prostate by immunocytochemistry. Prostate 1990;16:331–343.
16.
Murakoshi M, Inada R, Tagawa M, Makino M, Suzuki M, Mieda M, Honma S, Takezawa Y, Yamanaka H: Inhibitory influence of a new steroidal anti–androgen, TZP–4238, on prostatic hyperplasia in the beagle dog. Acta Pathol Jpn 1992;42:151–157.
17.
Laroque PA, Prahalada S, Molon–Noblot S, Bagdon WJ, Duprat P, Peter CP, Van Zwieten MJ: Quantitative evaluation of glandular and stromal compartment in hyperplastic dog prostates: Effect of 5–alpha–reductase inhibitors. Prostate 1995;27:121–128.
18.
Schulze H, Barrack ER: Immunocytochemical localization of estrogen receptors in spontaneous and experimentally induced canine benign prostatic hyperplasia. Prostate 1987;11: 145–162.
19.
Brolin J, Skoog L, Ekman P: Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate 1992;20:281–295.
20.
Miyamoto KK, McSherry SA, Dent GA, Sar M, Wilson EM, French FS, Sharief Y, Mohler JL: Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 1993;149:1015–1019.
21.
Kuiper GG, Enmark E, Pelto–Huikko M, Nilsson S, Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925–5930.
22.
Bouton MM, Pornin C, Grandadam JA: Estrogen regulation of rat prostate androgen receptor. J Steroid Biochem 1981;15:403–408.
23.
Bacher M, Rausch U, Goebel HW, Polzar B, Mannherz HG, Aumuller G: Stromal and epithelial cells from rat ventral prostate during androgen deprivation and estrogen treatment regulation of transcription. Exp Clin Endocrinol 1993;101:78–86.
24.
Ghelfi R, Corce A, Mangiagalli M: Pharmacokinetics of mepartricin. Note 1: Absorption and excretion of its insoluble form. Terap Antibiot Chemoter 1987;28:3–6.
25.
Shakutou S, Bandoh K, Yoshinaka Y, Kobayashi H, Yamanaka H: Effects of mepartricin, a polyene macrolide agent, on fecal excretion and serum concentration of estrogen and number of prostatic estrogen receptor in immature rats. Prostate 1999;38:17–27
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.